High-dose chemotherapy with busulfan and cyclophosphamide (Bu/Cy) and autologous stem cell rescue in patients with Hodgkin lymphoma

Eitemau Tebyg

• Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
  gan: Jo, Jae-Cheol, et al.
  Cyhoeddwyd: (2012)
• Once Daily IV Busulfan and Fludarabine (IV Bu-Flu) Compares Favorably with IV Busulfan and Cyclophosphamide (IV BuCy2) as Pretransplant Conditioning Therapy in AML/MDS
  gan: Andersson, Borje S., et al.
  Cyhoeddwyd: (2008)
• Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT)
  gan: Ramzi, Mani, et al.
  Cyhoeddwyd: (2020)
• Phase II Trial of High-Dose Rituximab with High-dose Cytarabine Mobilization Therapy and High-Dose Thiotepa, Busulfan, and Cyclophosphamide (R-TBC) Autologous Stem Cell Transplant in Patients with CNS Involvement by Non-Hodgkin Lymphoma
  gan: Chen, Yi-Bin, et al.
  Cyhoeddwyd: (2014)
• Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy
  gan: Farhan, Shatha, et al.
  Cyhoeddwyd: (2017)